(Q46622781)

23 December 2017

title

Imatinib mesylate for refractory acute myeloblastic leukemia harboring inv(16) and a C-KIT exon 8 mutation (English)

1 reference

23 December 2017

Acute myeloblastic leukemia

1 reference

1 reference

1 reference

Nanri T

1

1 reference

23 December 2017

Matsuno N

2

1 reference

23 December 2017

Kawakita T

3

1 reference

23 December 2017

Mitsuya H

4

1 reference

23 December 2017

Asou N

5

1 reference

23 December 2017

publication date

1 September 2005

1 reference

23 December 2017

published in

Leukemia

1 reference

23 December 2017

volume

19

1 reference

23 December 2017

issue

9

1 reference

23 December 2017

page(s)

1673-1675

1 reference

23 December 2017

The role of a Runt domain transcription factor AML1/RUNX1 in leukemogenesis and its clinical implications

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403889

Pathogenesis of acute myeloid leukaemia and inv(16)(p13;q22): a paradigm for understanding leukaemogenesis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403889

Dual mutations in the AML1 and FLT3 genes are associated with leukemogenesis in acute myeloblastic leukemia of the M0 subtype

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403889

Mutations in the receptor tyrosine kinase pathway are associated with clinical outcome in patients with acute myeloblastic leukemia harboring t(8;21)(q22;q22).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403889

KIT exon 8 mutations associated with core-binding factor (CBF)-acute myeloid leukemia (AML) cause hyperactivation of the receptor in response to stem cell factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403889

Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403889

Efficacy and safety of imatinib in adult patients with c-kit-positive acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403889

Imatinib mesylate in the treatment of Core Binding Factor leukemias with KIT mutations. A report of three cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403889

21 January 2018

Identifiers

DOI

10.1038/SJ.LEU.2403889

1 reference

23 December 2017

1 reference

23 December 2017